Literature DB >> 30526182

WFSBP guidelines on how to grade treatment evidence for clinical guideline development.

Alkomiet Hasan1, Borwin Bandelow2, Lakshmi N Yatham3, Michael Berk4,5, Peter Falkai1, Hans-Jürgen Möller1, Siegfried Kasper6.   

Abstract

OBJECTIVE AND METHODS: This paper reviews sources of data typically used in guideline development, available grading systems, their pros and cons, and the methods for evaluating risks of bias in publications, and proposes a revised method for grading evidence and recommendations for use in development of clinical treatment guidelines.
RESULTS: The new World Federation of Societies of Biological Psychiatry (WFSBP) grading system allows guideline developers to follow a multi-step approach of defining levels of evidence, applying criteria for grading (define the acceptability) and the grading of recommendations.
CONCLUSIONS: Further, these updated WFSBP recommendations for rating evidence and treatment recommendations provide a grading system that takes into account potential biases in sources of evidence in arriving at final ratings that are likely more clinically meaningful and pragmatic and thus should be used for the development of future treatment guidelines.

Keywords:  evidence-based psychiatry; grading evidence; guidelines; meta-analysis; randomized controlled trial

Mesh:

Year:  2019        PMID: 30526182     DOI: 10.1080/15622975.2018.1557346

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  6 in total

1.  Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.

Authors:  Rachael W Taylor; Lindsey Marwood; Emanuella Oprea; Valeria DeAngel; Sarah Mather; Beatrice Valentini; Roland Zahn; Allan H Young; Anthony J Cleare
Journal:  Int J Neuropsychopharmacol       Date:  2020-12-03       Impact factor: 5.176

Review 2.  Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis.

Authors:  Xenia M Hart; Christoph Hiemke; Luzie Eichentopf; Xenija M Lense; Hans Willi Clement; Andreas Conca; Frank Faltraco; Vincenzo Florio; Jessica Grüner; Ursula Havemann-Reinecke; Espen Molden; Michael Paulzen; Georgios Schoretsanitis; Thomas G Riemer; Gerhard Gründer
Journal:  Psychopharmacology (Berl)       Date:  2022-10-05       Impact factor: 4.415

3.  Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews.

Authors:  Xenia M Hart; Luzie Eichentopf; Xenija Lense; Thomas Riemer; Katja Wesner; Christoph Hiemke; Gerhard Gründer
Journal:  Front Psychiatry       Date:  2021-11-24       Impact factor: 4.157

4.  Key considerations in the pharmacological management of treatment-resistant depression.

Authors:  Mani Yavi; Ioline D Henter; Lawrence T Park; Carlos Zarate
Journal:  Expert Opin Pharmacother       Date:  2021-07-21       Impact factor: 3.889

5.  Evidence-Based Expert Consensus Regarding Long-Acting Injectable Antipsychotics for Schizophrenia from the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN).

Authors:  Kai-Chun Yang; Yin-To Liao; Yen-Kuang Yang; Shih-Ku Lin; Chih-Sung Liang; Ya-Mei Bai
Journal:  CNS Drugs       Date:  2021-07-27       Impact factor: 5.749

6.  Evaluation of evidence grades in psychiatry and psychotherapy guidelines.

Authors:  Lisa Löhrs; Mirjam Handrack; Ina Kopp; Frank Jessen; Elias Wagner; Peter Falkai; Astrid Röh; Wolfgang Strube; Alkomiet Hasan
Journal:  BMC Psychiatry       Date:  2020-10-12       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.